Skip to search formSkip to main contentSkip to account menu

MK 0646

Known as: MK-0646, MK0646 
National Institutes of Health

Related topics

Related topics

2 relations
Monoclonal Antibodies

Broader (1)

dalotuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
BackgroundIGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth… 
2013
2013
Therapy: Blockade of IGF-1R—not effective in neuroendocrine tumours
A phase II trial has demonstrated that insulin-like growth factor 1 receptor (IGF-1R) blockade in advanced neuroendocrine tumours… 
2012
2012
Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data
3587 Background: KRAS mutated metastatic colorectal cancer (mCRC) is inherently resistant to EGFR targeted therapy and carries an… 
2010
2010
Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.
4039 Background: MK-0646 binds to IGF-1R and blocks its interaction with IGF-I/ II ligands, enhances gemcitabine (G)-induced… 
2010
2010
A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs).
4163 Background: Preclinical studies have implicated the IGF-1 receptor in the progression of neuroendocrine tumors. A therapy… 
2010
2010
Optimal treatment of metastatic pancreatic cancer
Approximately 60% of patients with pancreatic cancer have metastatic disease at the time of diagnosis.1 Gemcitabine, which has… 
2010
2010
Abstract 2760: Phase I study of MK-0646, the humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced, previously untreated pancreatic…
BACKGROUND: MK-0646 binds to IGF-1R and blocks its interaction with the IGF-I/ II ligands, enhances gemcitabine (G)-induced… 
2010
2010
Abstract PR3: Preclinical and molecular profiling data suggest LumB breast cancer as a potential indication for co-targeting IGF1R and mTOR with MK-0646 and MK-8669
There has been increasing interest in developing cancer therapies targeting PI3K pathway nodes. However, inhibition of a single… 
2010
2010
Abstract LB-41: Histone deacetylase (HDAC) inhibition induces a resistance mechanism via the insulin-like growth factor-1 receptor (IGF-1R) signaling pathway: Rational basis for cotargeting of IGF-1R…
Background: Histone deacetylase (HDAC), which modulate chromatin structure and gene expression, has attracted attention as a… 
2009
2009
A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer.
4127 Background: Evidence of cross-talk between EGFR and IGFR signaling pathways provide a logical rationale for combining anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)